The German biopharmaceutical company BioNTech finds itself at a critical juncture following a significant divestment by its former pandemic partner. Pfizer, once an indispensable collaborator in COVID-19 vaccine development, has sold more than half its holdings in the company. This strategic shift comes as BioNTech reports conflicting financial signals: rising revenues coupled with persistent quarterly losses. The developments prompt market observers to question whether this marks the conclusion of the company’s most prosperous period or the commencement of a new chapter beyond pandemic-focused operations.
Financial Results Reveal Shifting Revenue Streams
Recent quarterly performance highlights the transitional phase BioNTech currently navigates. For the third quarter of 2025, the company recorded a 22% revenue increase to €1.52 billion. However, deeper examination reveals this growth stemmed predominantly from a $1.5 billion payment received through a cancer research collaboration with Bristol Myers Squibb. Meanwhile, COVID-19 vaccine revenues demonstrated a continuing downward trajectory.
The quarter concluded with a net loss of €28.7 million, translating to a per-share loss of €0.12. With a profit margin of approximately -1.9%, the company continues to operate at a deficit while aggressively developing its oncology pipeline.
Strategic Partner Scales Back Investment
In a move that captured market attention, Pfizer substantially reduced its BioNTech stake by 54.7%. The American pharmaceutical giant now maintains only about 1.66 million depositary receipts—a fraction of its previous position. Although both corporations emphasize their operational collaboration remains unchanged, the financial retreat signals diminished commitment to what was once a showcase partnership.
Should investors sell immediately? Or is it worth buying BioNTech?
This development creates dual pressure for BioNTech shares, simultaneously eroding confidence through the withdrawal of an industry heavyweight and underscoring the definitive conclusion of the pandemic’s prosperous years.
Revised Outlook and Therapeutic Transition
Management has responded to these challenges by significantly raising full-year guidance. BioNTech now anticipates 2025 revenues between €2.6 and €2.8 billion. This upgraded forecast, however, primarily reflects the Bristol Myers Squibb partnership rather than organic growth, serving as a financial bridge toward an uncertain future.
The company’s strategic pivot from pandemic blockbusters to cancer treatments represents a precarious transition. Success largely depends on experimental antibody Pumitamig, co-developed with Bristol Myers Squibb. The competitive oncology landscape presents greater challenges and less predictability compared to the previously lucrative vaccine business, leaving BioNTech’s transformation outcome uncertain.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from November 19 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 19.
BioNTech: Buy or sell? Read more here...
